FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts

Table 2 Results of univariate and multivariate analysis for time to progression with FOLFIRI

	Progression	Univariate analysis			Multivariate analysis
	Yes/no (57/1)	HR	95% CI	P value	HR	95% CI	P value
Primary tumor location1				0.687
Body or tail	18/0	1
Head	28/1	0.883	(0.483-1.615)
Stage at the diagnosis				0.666			0.652
Resectable	22/0	1			1
Locally advanced	15/1	1.235	(0.631-2.418)		1.394	(0.662-2.939)
Metastatic	20/0	0.905	(0.490-1.674)		1.299	(0.626-2.695)
Previous surgery				0.659
No	37/1	1
Yes	20/0	0.882	(0.506-1.539)
Previous radiotherapy				0.411			0.168
No	44/0	1			1
Yes	13/1	1.305	(0.692-2.459)		1.770	(0.786-3.987)
Number of previous chemotherapy lines				0.284			0.026
1	16/0	1			1
2	36/1	0.649	(0.350-1.204)	0.170	0.385	(0.193-0.770)
3	5/0	1.128	(0.411-3.096)	0.814	0.554	(0.177-1.735)
Liver metastases				0.531			0.564
No	9/0	1			1
Yes	48/1	0.793	(0.383-1.640)		1.298	(0.535-3.151)
WHO performans status				< 0.0001			< 0.0001
0	24/0	1			1
1	22/1	1.325	(0.731-2.399)		1.431	(0.745-2.748)
2	11/0	16.036	(5.926-43.394)		29.255	(9.278-92.248)
Type of FOLFIRI regimen				0.124
FOLFIRI-1	50/0	1
FOLFIRI-3	7/1	0.503	(0.210-1.207)

HR: Hazard ratio; WHO: World Health Organization.

¹Data available in 47 out of 58 cases.